Sight Sciences Inc (SGHT)

Currency in USD
4.30
-0.03(-0.69%)
Closed·
4.35+0.05(+1.16%)
·
SGHT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.154.37
52 wk Range
2.819.24
Key Statistics
Prev. Close
4.33
Open
4.37
Day's Range
4.15-4.37
52 wk Range
2.81-9.24
Volume
184.24K
Average Volume (3m)
333.68K
1-Year Change
50.3497%
Book Value / Share
1.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SGHT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.34
Upside
+93.90%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Sight Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.34
(+93.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Buy---Maintain05-03-2026
Citi
Hold6.50+51.16%9.10Maintain05-03-2026
Stifel
Buy8.00+86.05%6.00Maintain02-03-2026
William Blair
Buy---New Coverage30-01-2026
Piper Sandler
Buy9.00+109.30%5.00Upgrade05-01-2026

Sight Sciences Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue reached $19.7M, up 13% YoY and beating estimates by 6.2%, driven by glaucoma and dry eye segment growth
  • EPS of -$0.24 missed forecast of -$0.17 by 41%, with net loss of $13M highlighting ongoing profitability challenges
  • Company maintains strong balance sheet with $85M cash and 86% gross margin; improved cash management noted
  • OMNI Ultra launch and dry eye market expansion expected to drive future growth; continued innovation focus emphasized
  • Stock declined 0.69% post-earnings to $4.33; faces litigation risks with Alcon and competitive pressures in core segments
Last Updated: 07-05-2026, 03:08 am
Read Full Transcript

Earnings

Latest Release
06-05-2026
EPS / Forecast
-0.24 / -0.17
Revenue / Forecast
19.7M / 18.55M
EPS Revisions
Last 90 days

SGHT Income Statement

Compare SGHT to Peers and Sector

Metrics to compare
SGHT
Peers
Sector
Relationship
P/E Ratio
−6.1x−4.8x−0.5x
PEG Ratio
−0.21−0.160.00
Price/Book
3.7x3.0x2.6x
Price / LTM Sales
3.0x2.7x3.2x
Upside (Analyst Target)
102.4%44.3%48.3%
Fair Value Upside
Unlock15.5%5.6%Unlock

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.11M11.23%26.45M
Other Institutional Investors
27.10M49.82%117.36M
Public Companies & Retail Investors
21.19M38.95%91.75M
Total
54.4M100.00%235.57M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Allegro Investment Inc.9.35%50,86,92022,026
Allegro Investment Fund, L.P.9.35%50,86,92022,026

FAQ

What Is the Sight Sciences (SGHT) Share Price Today?

The Sight Sciences share price today is 4.30.

What is the current Sight Sciences (SGHT) share price and day range?

As of 07-05-2026, the Sight Sciences share price is 4.30, with a previous close of 4.33. The share price has ranged from 4.15 to 4.37 today, while the 52-week range spans from 2.81 to 9.24.

What Is the Sight Sciences Market Cap?

As of today, Sight Sciences market cap is 233.94M.

What Is the Sight Sciences (SGHT) Share Price Target?

The average 12-month share price target for Sight Sciences is 8.34, with a high estimate of 12 and a low estimate of 4.35. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +93.90% Upside potential.

What Is Sight Sciences's Earnings Per Share (TTM)?

The Sight Sciences EPS (TTM) is -0.74.

When Is the Next Sight Sciences Earnings Date?

Sight Sciences will release its next earnings report on 06-08-2026.

From a Technical Analysis Perspective, Is SGHT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Sight Sciences Trade On?

Sight Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Sight Sciences?

The stock symbol for Sight Sciences is "SGHT."

How Many Times Has Sight Sciences Stock Split?

Sight Sciences has split 0 times.

How Many Employees Does Sight Sciences Have?

Sight Sciences has 186 employees.

What Is the SGHT After Hours Price?

SGHT's last after hours stock price is 4.35, the stock has changed by 0.05, or 1.16%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.